Recent Posts
- Egret Therapeutics Signs Memorandum of Understanding with Genexine Toward Full Ownership of Lead PD-1 Agonist Asset GX-P1 (EGT-101)
- Turret Capital Launches Sable, a Biotech-Driven Beauty Brand Advancing Body Contouring and Aesthetic Longevity
- Turret Capital Launches “The Foundry”: A Global Youth Innovation Platform to Shape the Future of Healthcare
- Egret Therapeutics Appoints Dr. Geoffrey Ling to Scientific Advisory Board
- Egret Therapeutics Announces Appointment Ron Cohen, M.D. to its Board of Directors
Recent Comments